ScholarIQanswers from OpenAlex & ORCID
Hiroaki Shimokawa
ResearcherPublications, citations & collaboration network
Hiroaki Shimokawa is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Hiroaki Shimokawa have?
ScholarIQindexed works
Hiroaki Shimokawa has 1,687 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hiroaki Shimokawa have?
ScholarIQcitation count
Hiroaki Shimokawa has 71,441 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Hiroaki Shimokawa?
ScholarIQh-index
Hiroaki Shimokawa has an h-index of 127 in OpenAlex.
What is the i10-index of Hiroaki Shimokawa?
ScholarIQi10-index
Hiroaki Shimokawa has an i10-index of 661 in OpenAlex.
What is the ORCID of Hiroaki Shimokawa?
ScholarIQorcid
The ORCID for Hiroaki Shimokawa is on the source record.
What is the OpenAlex record for Hiroaki Shimokawa?
ScholarIQopenalex
The OpenAlex for Hiroaki Shimokawa is on the source record.
What are the most-cited papers on Hiroaki Shimokawa?
ScholarIQmost cited works
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker, Brendan M. Everett, Tom Thurén, Jean MacFadyen, William H. Chang, Christie M. Ballantyne, Francisco Antônio Helfenstein Fonseca, José Carlos Nicolau, Wolfgang Köenig, Stefan D. Anker, John J.P. Kastelein, Jan H. Cornel, Prem Pais, Daniel Pella, Jacques Genest, Renata Cífková, Alberto Lorenzatti, Tamás Forster, Zhanna Kobalava, L Vida-Simiti, Marcus Flather, Hiroaki Shimokawa, Hisao Ogawa, Mikael Dellborg, Paulo R.F. Rossi, Roland P.T. Troquay, Peter Libby, Robert J. Glynn
Heart Failure: Preventing Disease and Death Worldwide
Piotr Ponikowski, Stefan D. Anker, Khalid F. AlHabib, Martín Cowie, Thomas Force, Shengshou Hu, Tiny Jaarsma, Henry Krum, Vishal Rastogi, Luís Eduardo Paim Rohde, Umesh Chandra Samal, Hiroaki Shimokawa, Bambang Budi Siswanto, Karen Sliwa, Gerasimos Filippatos
International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology
Jelena R. Ghadri, Ilan S. Wittstein, Abhiram Prasad, Scott W. Sharkey, Keigo Dote, Yoshihiro J. Akashi, Victoria L. Cammann, Filippo Crea, Leonarda Galiuto, Walter Desmet, Tetsuro Yoshida, Roberto Manfredini, Ingo Eitel, Masami Kosuge, Holger Nef, Abhishek Deshmukh, Amir Lerman, Eduardo Bossone, Rodolfo Citro, Takashi Ueyama, Domenico Corrado, Satoshi Kurisu, Frank Ruschitzka, David E. Winchester, Alexander R. Lyon, Elmir Ömerovic, Jeroen J. Bax, P. Meimoun, Guiseppe Tarantini, Charanjit S. Rihal, Shams Y.-Hassan, Federico Migliore, John D. Horowitz, Hiroaki Shimokawa, Thomas F. Lüscher, Christian Templin
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M. Ridker, Jean MacFadyen, Tom Thurén, Brendan M Everett, Peter Libby, Robert J. Glynn, Paul M. Ridker, Alberto Lorenzatti, Henry Krum, George Varigos, Peter Siostrzonek, Peter Sinnaeve, Francisco Antônio Helfenstein Fonseca, José Carlos Nicolau, Nina Gotcheva, Jacques Genest, Yong Huo, Miguel Urina‐Triana, Davor Miličić, Renata Cífková, Riina Vettus, Wolfgang Köenig, S.D. Anker, Athanasios Manolis, Fernando Wyss, Tamás Forster, Axel F. Sigurðsson, Prem Pais, Alessandro Fucili, Hisao Ogawa, Hiroaki Shimokawa, Irina Veze, Birutė Petrauskienė, Leon Salvador, John J.P. Kastelein, Jan H. Cornel, Tor Ole Klemsdal, Félix Medina, Andrzej Budaj, L Vida-Simiti, Zhanna Kobalava, Petar Otašević, Daniel Pella, Mitja Lainščak, Ki‐Bae Seung, Patrick Commerford, Mikael Dellborg, Marc Y. Donath, Juey‐Jen Hwang, Hakan Kültürsay, Marcus Flather, Christie M. Ballantyne, Seth Bilazarian, William H. Chang, Cara East, Brendan Everett, Les B. Forgosh, Robert J. Glynn, Barry Harris, Peter Libby, M Ligueros, Tom Thurén, Erin A. Bohula, Bindu Charmarthi, Susan Cheng, Sherry Chou, Jacqueline Suk Danik, Graham T. McMahon, Bradley A. Maron, MingMing Ning, Benjamin A. Olenchock, Reena L. Pande, Todd S. Perlstein, Aruna D. Pradhan, Natalia S. Rost, Aneesh B. Singhal, Viviany R. Taqueti, Nancy Wei, Howard A. Burris, Angela Cioffi, Anne Marie Dalseg, Nilanjan Ghosh, Julie R. Gralow, Tina Mayer, Hope S. Rugo, Vance G. Fowler, Ajit P. Limaye, Sara E. Cosgrove, Donald P. Levine, Renato D. Lópes, John Scott, Tom Thurén, M Ligueros, Robert Hilkert, Georgia Tamesby, Carolyn Mickel, Brian Manning, Julian Woelcke, Monique Tan, S Manfreda
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Paul M. Ridker, Jean MacFadyen, Brendan M Everett, Peter Libby, Tom Thurén, Robert J. Glynn, Paul M. Ridker, Jean MacFadyen, Brendan M Everett, Peter Libby, Tom Thurén, Robert J. Glynn, John J.P. Kastelein, Wolfgang Köenig, Jacques Genest, Alberto Lorenzatti, George Varigos, Peter Siostrzonek, Peter Sinnaeve, Francisco Antônio Helfenstein Fonseca, José Carlos Nicolau, Nina Gotcheva, Yong Huo, Miguel Urina‐Triana, Davor Miličić, Renata Cífková, Riina Vettus, S.D. Anker, Athanasios Manolis, Fernando Wyss, Tamás Forster, Axel F. Sigurðsson, Prem Pais, Alessandro Fucili, Hisao Ogawa, Hiroaki Shimokawa, Irina Veze, Birutė Petrauskienė, Leon Salvador, Jan H. Cornel, Tor Ole Klemsdal, Félix Medina, Andrzej Budaj, L Vida-Simiti, Zhanna Kobalava, Petar Otašević, Daniel Pella, Mitja Lainščak, Ki‐Bae Seung, Patrick Commerford, Mikael Dellborg, Marc Y. Donath, Juey‐Jen Hwang, Hakan Kültürsay, Marcus Flather, Christie M. Ballantyne, Seth Bilazarian, William H. Chang, Cara East, Les B. Forgosh, Barry Harris, M Ligueros